DE69739277D1 - N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform - Google Patents

N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Info

Publication number
DE69739277D1
DE69739277D1 DE69739277T DE69739277T DE69739277D1 DE 69739277 D1 DE69739277 D1 DE 69739277D1 DE 69739277 T DE69739277 T DE 69739277T DE 69739277 T DE69739277 T DE 69739277T DE 69739277 D1 DE69739277 D1 DE 69739277D1
Authority
DE
Germany
Prior art keywords
liposomenic
phosphatidylethanolamine
acyl
formulation
medium active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739277T
Other languages
English (en)
Inventor
Paul R Meers
Tong Shangguan
Shaukat Ali
Andrew S Janoff
Charles Pak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transave LLC
Original Assignee
Transave LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave LLC filed Critical Transave LLC
Application granted granted Critical
Publication of DE69739277D1 publication Critical patent/DE69739277D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
DE69739277T 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform Expired - Lifetime DE69739277D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2855796P 1996-10-15 1996-10-15
PCT/US1997/018112 WO1998016199A1 (en) 1996-10-15 1997-10-15 N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

Publications (1)

Publication Number Publication Date
DE69739277D1 true DE69739277D1 (de) 2009-04-09

Family

ID=21844115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739277T Expired - Lifetime DE69739277D1 (de) 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Country Status (13)

Country Link
US (2) US6120797A (de)
EP (1) EP0966267B1 (de)
AT (1) ATE423547T1 (de)
AU (1) AU725257B2 (de)
CA (1) CA2276269C (de)
DE (1) DE69739277D1 (de)
ES (1) ES2321769T3 (de)
HU (1) HUP0000522A3 (de)
IL (1) IL130822A (de)
NO (1) NO993257L (de)
NZ (2) NZ336538A (de)
SK (1) SK283760B6 (de)
WO (1) WO1998016199A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467789B2 (ja) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
CA2309548A1 (en) 1997-11-14 1999-05-27 Skyepharma Inc. Production of multivesicular liposomes
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
WO2003004646A2 (en) * 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
AU2002322024B2 (en) * 2001-05-31 2008-05-08 Pacira Pharmaceuticals, Inc. Encapsulation of nanosuspensions in liposomes and microspheres
EP1461014B1 (de) * 2001-12-04 2021-07-14 Ben Gurion University Of The Negev Research And Development Authority Amphiphile verbindungen und vesikel/liposome für das organspezifische arzneimittel-targeting
AU2003207462A1 (en) * 2002-01-09 2003-07-30 Transave, Inc. Efficient liposomal encapsulation under mild conditions
CA2472462A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
US20090191259A1 (en) * 2002-01-09 2009-07-30 Transave, Inc. Efficient liposomal encapsulation
CA2475630C (en) * 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
CA2490959C (en) * 2002-07-02 2013-04-16 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
CN1852721B (zh) * 2003-07-31 2013-03-27 得克萨斯大学体系董事会 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
ITMI20041280A1 (it) * 2004-06-24 2004-09-24 Hunza Di Pistolesi Elvira & C Preparazione farmaceutiche dietetiche e-o cosmetiche per il trattamento dell'obesita' dell'alopecia della cellulite e dell'invecchiamento cutaneo
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US20070212703A1 (en) * 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
RU2457854C2 (ru) * 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
WO2008030818A2 (en) * 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
KR20110033118A (ko) * 2008-07-08 2011-03-30 케미 에스.피.에이. Ｎ-아실-포스파티딜-에탄올아민의 생산 방법
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
DK2440241T3 (en) 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US9642817B2 (en) 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
CA2778678A1 (en) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
US20130273561A1 (en) * 2010-10-29 2013-10-17 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
JP6608422B2 (ja) 2014-03-25 2019-11-20 ザ ガバメント オブ ザ ユナイテッド ステイツ，アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
EP3370730A4 (de) 2015-11-06 2019-07-31 Adjuvance Technologies, Inc. Triterpensaponinanaloga
CA3040258A1 (en) * 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
KR20200034668A (ko) 2017-05-08 2020-03-31 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 융합을 촉진시키기 위한 조성물 및 그의 용도
KR20200098476A (ko) 2017-10-16 2020-08-20 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents

Also Published As

Publication number Publication date
CA2276269C (en) 2008-09-02
CA2276269A1 (en) 1998-04-23
ATE423547T1 (de) 2009-03-15
US6120797A (en) 2000-09-19
IL130822A (en) 2005-12-18
NO993257L (no) 1999-07-28
HUP0000522A3 (en) 2000-10-30
ES2321769T3 (es) 2009-06-10
SK99399A3 (en) 2000-06-12
EP0966267B1 (de) 2009-02-25
WO1998016199A1 (en) 1998-04-23
EP0966267A4 (de) 2006-02-01
US6294191B1 (en) 2001-09-25
AU4672397A (en) 1998-05-11
AU725257B2 (en) 2000-10-12
SK283760B6 (sk) 2004-01-08
EP0966267A1 (de) 1999-12-29
IL130822A0 (en) 2001-07-24
NZ514133A (en) 2001-09-28
NO993257D0 (no) 1999-06-30
NZ336538A (en) 2001-11-30
HUP0000522A1 (hu) 2000-09-28

Similar Documents

Publication Publication Date Title
DE69739277D1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL140710A0 (en) Pulmonary delivery of active agents
BG104247A (en) Resorcinol derivatives
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
DE69905170D1 (en) Thiazolopyrimidinderivate
PL347671A1 (en) Compounds and compositions for delivering active agents
ATE244015T1 (de) Formulierungen fuer faktor ix
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
SE9802937D0 (sv) Novel compounds
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
EP1073447A4 (de) N1 modifizierte glycopeptide
NO20005548D0 (no) Mykobakterieinhibitorer
ATE345778T1 (de) (ester)-lysolecithine in liposomen
DE69709891T2 (de) Chitosan enthaltende zusammensetzung
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
GB9818445D0 (en) Medicaments
MX9600383A (es) W-ifn como un agente anti-hiv.
MX9700439A (es) Uso de(s)-adenosil-l-metionina (same) y sus sales fisiologicamente compatibles para tratamiento de daño de reperfusion activado por isquemia focal temporal.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition